Cindy Kortepeter

1.3k total citations
30 papers, 787 citations indexed

About

Cindy Kortepeter is a scholar working on Toxicology, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Cindy Kortepeter has authored 30 papers receiving a total of 787 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Toxicology, 6 papers in Pathology and Forensic Medicine and 6 papers in Oncology. Recurrent topics in Cindy Kortepeter's work include Pharmacovigilance and Adverse Drug Reactions (10 papers), Multiple Sclerosis Research Studies (5 papers) and Polyomavirus and related diseases (5 papers). Cindy Kortepeter is often cited by papers focused on Pharmacovigilance and Adverse Drug Reactions (10 papers), Multiple Sclerosis Research Studies (5 papers) and Polyomavirus and related diseases (5 papers). Cindy Kortepeter collaborates with scholars based in United States and Japan. Cindy Kortepeter's co-authors include Allen Brinker, Christine Chamberlain, Susan Bersoff‐Matcha, William H Chong, Alfred Sorbello, Mark Avigan, David Croteau, Mónica Muñoz, Syed Rizwanuddin Ahmad and Julie Beitz and has published in prestigious journals such as SHILAP Revista de lepidopterología, Annals of Internal Medicine and Gastroenterology.

In The Last Decade

Cindy Kortepeter

29 papers receiving 761 citations

Peers

Countries citing papers authored by Cindy Kortepeter

Since Specialization

Citations

This map shows the geographic impact of Cindy Kortepeter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cindy Kortepeter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cindy Kortepeter more than expected).

Fields of papers citing papers by Cindy Kortepeter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cindy Kortepeter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cindy Kortepeter. The network helps show where Cindy Kortepeter may publish in the future.

Co-authorship network of co-authors of Cindy Kortepeter

This figure shows the co-authorship network connecting the top 25 collaborators of Cindy Kortepeter. A scholar is included among the top collaborators of Cindy Kortepeter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cindy Kortepeter. Cindy Kortepeter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Immune-mediated colitis associated with ocrelizumab: A new safety risk 2023 ·Multiple Sclerosis Journal ·Tiffany Kim, Allen Brinker, David Croteau, Paul R. Lee, Laura Baldassari, J. Clarke Stevens, (unknown), (unknown), (unknown), (unknown), Cindy Kortepeter	9
2	Assessment of the Impact of Mandated Postmarketing Pediatric‐Focused Safety Reviews on Safety‐Related Regulatory Actions 2013–2019 2023 ·Clinical Pharmacology & Therapeutics ·(unknown), (unknown), (unknown), (unknown), Eileen Wu, Mónica Muñoz, Cindy Kortepeter, Ellen Pinnow, Gerald J. Dal Pan	1
3	Postmarket Assessment for Drugs and Biologics Used in Dermatology and Cutaneous Adverse Drug Reactions 2022 ·Dermatologic Clinics ·(unknown), Cindy Kortepeter, Mónica Muñoz	2
4	Leveraging Case Narratives to Enhance Patient Age Ascertainment from Adverse Event Reports 2021 ·Pharmaceutical Medicine ·Phuong Pham, (unknown), Eileen Wu, (unknown), Rongmei Zhang, Yong Ma, Cindy Kortepeter, Mónica Muñoz	8
5	An Evaluation of Postmarketing Reports with an Outcome of Death in the US FDA Adverse Event Reporting System 2020 ·Drug Safety ·(unknown), S. Christopher Jones, Cindy Kortepeter, Gerald J. Dal Pan, Mónica Muñoz	14
6	Expanding spectrum of opportunistic infections associated with dimethyl fumarate 2020 ·Multiple Sclerosis Journal ·Tiffany Kim, David Croteau, Allen Brinker, David Jones, Paul R. Lee, Cindy Kortepeter	5
7	Towards Automating Adverse Event Review: A Prediction Model for Case Report Utility 2020 ·Drug Safety ·Mónica Muñoz, Gerald J. Dal Pan, Yu‐Jung Jenny Wei, Chris Delcher, Hong Xiao, Cindy Kortepeter, Almut G. Winterstein	21
8	Tumefactive multiple sclerosis in association with fingolimod initiation and discontinuation 2020 ·Multiple Sclerosis Journal ·David Croteau, (unknown), Allen Brinker, Cindy Kortepeter	12
9	Fournier Gangrene Associated With Sodium–Glucose Cotransporter-2 Inhibitors 2019 ·Annals of Internal Medicine ·Susan Bersoff‐Matcha, Christine Chamberlain, (unknown), Cindy Kortepeter, William H Chong	4
10	Hemophagocytic lymphohistiocytosis associated with the use of lamotrigine 2019 ·Neurology ·Tiffany Kim, (unknown), Cindy Kortepeter, Allen Brinker, Peter Waldron	12
11	Fournier Gangrene Associated With Sodium–Glucose Cotransporter-2 Inhibitors 2019 ·Annals of Internal Medicine ·Susan Bersoff‐Matcha, Christine Chamberlain, (unknown), Cindy Kortepeter, William H Chong	174
12	Evaluation of Postmarketing Reports from Industry-Sponsored Programs in Drug Safety Surveillance 2018 ·Drug Safety ·Lisa Harinstein, (unknown), Cindy Kortepeter, Mónica Muñoz, Eileen Wu, Gerald J. Dal Pan	14
13	An Evaluation of “Drug Ineffective” Postmarketing Reports in Drug Safety Surveillance 2018 ·Drugs - Real World Outcomes ·(unknown), Cindy Kortepeter, Mónica Muñoz, Eileen Wu, Gerald J. Dal Pan	15
14	Liver injury associated with dimethyl fumarate in multiple sclerosis patients 2017 ·Multiple Sclerosis Journal ·Mónica Muñoz, (unknown), Cindy Kortepeter, Robert Levin, Mark Avigan	28
15	Central Nervous System Herpes Simplex and Varicella Zoster Virus Infections in Natalizumab-Treated Patients 2013 ·Clinical Infectious Diseases ·(unknown), Alfred Sorbello, Cindy Kortepeter, (unknown)	80
16	Progressive multifocal leukoencephalopathy after natalizumab discontinuation 2013 ·Annals of Neurology ·(unknown), Alfred Sorbello, Cindy Kortepeter, (unknown)	38
17	Clinically significant liver injury in patients treated with natalizumab 2010 ·Alimentary Pharmacology & Therapeutics ·(unknown), (unknown), Cindy Kortepeter, Mark Avigan	56
18	Clinical Profile of Oxcarbazepine-Related Angioneurotic Edema: Case Report and Review 2007 ·Pediatric Neurology ·James Knudsen, (unknown), Cindy Kortepeter, Yasser M. Awaad	9
19	Renal Failure Associated with the Use of Celecoxib and Rofecoxib 2002 ·Drug Safety ·Syed Rizwanuddin Ahmad, Cindy Kortepeter, Allen Brinker, Min Chen, Julie Beitz	85
20	Possible Short-Term Memory Loss Associated with Nafarelin Acetate 1992 ·Annals of Pharmacotherapy ·Cindy Kortepeter, (unknown), Richard A. Ferrell	7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact